Top Markets
#1 Islamic Coin Islamic Coin +151.32%
#2 Akedo Akedo +76.22%
#3 Glidr Glidr +51.75%
#4 DOVU DOVU +48.30%
#5 Velvet Velvet +34.72%
#6 Black Phoenix Black Phoenix +34.06%
#7 Cross Cross +32.03%
#8 Cap Cap +22.74%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.58%
#10 DoubleZero DoubleZero +14.87%
Coin of the day
Islamic Coin Islamic Coin
設定
言語
日本
通貨
USD
テーマ
Burzynski Research Institute, Inc. Burzynski Research Institute, Inc.

Burzynski Research Institute, Inc.

BZYR
株式のランク #39234
Burzynski Research Institute, Inc. engages in the research and development of... Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting services. The company was founded in 1977 and is headquartered in Houston, Texas.
株価
$0.0045
最終同期: 2026-08-13
時価総額
$591.52K
変化（1日）
-10.00%
変化（1年）
-86.76%
国
US
取引 Burzynski Research Institute, Inc. (BZYR)

カテゴリー

Healthcare
Burzynski Research Institute, Inc.（BZYR）の収益
Aug 2026 時点の収益 TTM: 0
Burzynski Research Institute, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Burzynski Research Institute, Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 $2.54B -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 $830.81M -
US